for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Business

Breakingviews TV: Going Loxo

Posted

Eli Lilly is paying a huge premium for the cancer-treating upstart and might not get a return for years. But Antony Currie and Robert Cyran explain that Loxo’s appeal lies in how it looks for what causes cancer, not where it occurs. That could be a big money-spinner.

Business

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up